> Osiris Therapeutics has inked a deal with the U.S. Defense Department to supply a potential $224 million worth of Prochymal for use in treating military personnel exposed to radiation. Release
> Osiris also regained all worldwide rights to Prochymal. Release
> Baxter International and Nektar Therapeutics are teaming up to investigate new therapies for a rare form of hemophilia. Report
> BrainStorm Cell Therapeutics has expanded its collaboration with Rutgers University aimed at curing spinal cord injuries through adult stem cell research. Release
> Jazz Pharmaceuticals has received orphan drug designation for an experimental epilepsy therapy. Report
> Waltham, MA-based Magen BioSciences has acquired the rights to dermatology compounds from Eli Lilly. Report
> Making a living off pharmaceutical companies suddenly isn't so lucrative: IMS Health, the market research company responsible for so much of the hard data on drug sales, is laying off about 10 percent of its work force. Report
> Celgene announced that it expects fiscal 2007 profits to double to $1.05 per share, as sales of its cancer drug Revlimid skyrocket. Report
> As if Amgen didn't have enough to worry about with its anemia drugs under fire. The company is defending itself against charges of bull-whipping sales reps into marketing drugs off label and violating patients' privacy. Report
And Finally... A pharma nightmare with an English accent: The UK government wants to slash prices for prescription drugs by 10 percent. Report